Difference between revisions of "Template:Ionotropic glutamate receptor modulators"
Jump to navigation
Jump to search
imported>Medgirl131 (Undid revision 798841013 by Medgirl131 (talk)) |
imported>Medgirl131 |
||
| (16 intermediate revisions by 7 users not shown) | |||
| Line 3: | Line 3: | ||
| title = [[Ionotropic glutamate receptor]] [[receptor modulator|modulator]]s | | title = [[Ionotropic glutamate receptor]] [[receptor modulator|modulator]]s | ||
| state = {{{state<includeonly>|collapsed</includeonly>}}} | | state = {{{state<includeonly>|collapsed</includeonly>}}} | ||
| − | | | + | | bodyclass = hlist |
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| Line 18: | Line 18: | ||
* [[Quisqualic acid]] | * [[Quisqualic acid]] | ||
* [[Willardiine]]; ''Positive allosteric modulators:'' [[Aniracetam]] | * [[Willardiine]]; ''Positive allosteric modulators:'' [[Aniracetam]] | ||
| + | * [[BIIB-104|BIIB-104 (PF-04958242)]] | ||
* [[Cyclothiazide]] | * [[Cyclothiazide]] | ||
* [[CX-516]] | * [[CX-516]] | ||
| Line 39: | Line 40: | ||
* [[Oxiracetam]] | * [[Oxiracetam]] | ||
* [[PEPA (drug)|PEPA]] | * [[PEPA (drug)|PEPA]] | ||
| − | |||
* [[Piracetam]] | * [[Piracetam]] | ||
* [[Pramiracetam]] | * [[Pramiracetam]] | ||
| Line 68: | Line 68: | ||
* [[Cyclopropane]] | * [[Cyclopropane]] | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
* [[Evans blue]] | * [[Evans blue]] | ||
* [[GYKI-52466]] | * [[GYKI-52466]] | ||
| Line 78: | Line 78: | ||
* [[Pregnenolone sulfate]] | * [[Pregnenolone sulfate]] | ||
* [[Sevoflurane]] | * [[Sevoflurane]] | ||
| − | * [[Talampanel]] | + | * [[Talampanel]]; ''Unknown/unsorted antagonists:'' [[Minocycline]] |
| group2 = {{abbrlink|KAR|Kainate receptor}} | | group2 = {{abbrlink|KAR|Kainate receptor}} | ||
| Line 117: | Line 117: | ||
* [[UBP-302]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | * [[UBP-302]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
* [[Evans blue]] | * [[Evans blue]] | ||
* [[NS-3763]] | * [[NS-3763]] | ||
| Line 162: | Line 162: | ||
* [[Epipregnanolone sulfate]] | * [[Epipregnanolone sulfate]] | ||
* [[Pregnenolone sulfate]] | * [[Pregnenolone sulfate]] | ||
| + | * [[SAGE-201]] | ||
| + | * [[SAGE-301]] | ||
* [[SAGE-718]] | * [[SAGE-718]] | ||
| Line 191: | Line 193: | ||
* [[ACEA-1011]] | * [[ACEA-1011]] | ||
* [[ACEA-1328]] | * [[ACEA-1328]] | ||
| + | * [[Apimostinel|Apimostinel (NRX-1074)]] | ||
* [[AV-101]] | * [[AV-101]] | ||
* [[Carisoprodol]] | * [[Carisoprodol]] | ||
* [[CGP-39653]] | * [[CGP-39653]] | ||
* [[CNQX]] | * [[CNQX]] | ||
| + | * [[Cycloserine|<small>D</small>-Cycloserine]] | ||
* [[DNQX]] | * [[DNQX]] | ||
* [[Felbamate]] | * [[Felbamate]] | ||
| Line 210: | Line 214: | ||
* [[MRZ 2/576]] | * [[MRZ 2/576]] | ||
* [[PNQX]] | * [[PNQX]] | ||
| + | * [[Rapastinel|Rapastinel (GLYX-13)]] | ||
* [[ZD-9379]]; ''Polyamine site antagonists:'' [[Arcaine]] | * [[ZD-9379]]; ''Polyamine site antagonists:'' [[Arcaine]] | ||
* [[Co 101676]] | * [[Co 101676]] | ||
| Line 225: | Line 230: | ||
* [[Alpha-Endopsychosin|α-Endopsychosin]] | * [[Alpha-Endopsychosin|α-Endopsychosin]] | ||
* [[Alaproclate]] | * [[Alaproclate]] | ||
| + | * [[Alazocine|Alazocine (SKF-10047)]] | ||
* [[Amantadine]] | * [[Amantadine]] | ||
* [[Aptiganel]] | * [[Aptiganel]] | ||
| Line 237: | Line 243: | ||
* [[Dexoxadrol]] | * [[Dexoxadrol]] | ||
* [[Dextrallorphan]] | * [[Dextrallorphan]] | ||
| + | * [[Dextromethadone]] | ||
* [[Dextromethorphan]] | * [[Dextromethorphan]] | ||
* [[Dextrorphan]] | * [[Dextrorphan]] | ||
| Line 255: | Line 262: | ||
* [[Lanicemine]] | * [[Lanicemine]] | ||
* [[Levomethadone]] | * [[Levomethadone]] | ||
| + | * [[Levomethorphan]] | ||
| + | * [[Levomilnacipran]] | ||
| + | * [[Levorphanol]] | ||
* [[Loperamide]] | * [[Loperamide]] | ||
* [[Memantine]] | * [[Memantine]] | ||
* [[Methadone]] | * [[Methadone]] | ||
* [[Methorphan]] | * [[Methorphan]] | ||
| − | |||
* [[Methoxetamine]] | * [[Methoxetamine]] | ||
* [[Methoxphenidine]] | * [[Methoxphenidine]] | ||
* [[Milnacipran]] | * [[Milnacipran]] | ||
* [[Morphanol]] | * [[Morphanol]] | ||
| − | |||
* [[NEFA (drug)|NEFA]] | * [[NEFA (drug)|NEFA]] | ||
| − | |||
* [[Neramexane]] | * [[Neramexane]] | ||
* [[Nitromemantine]] | * [[Nitromemantine]] | ||
| Line 310: | Line 317: | ||
* [[Diethyl ether]] | * [[Diethyl ether]] | ||
* [[Enflurane]] | * [[Enflurane]] | ||
| − | * [[Ethanol]] | + | * [[Alcohol (drug)|Ethanol (alcohol)]] |
* [[Halothane]] | * [[Halothane]] | ||
* [[Hexanol]] | * [[Hexanol]] | ||
| Line 327: | Line 334: | ||
* [[Bumetanide]] | * [[Bumetanide]] | ||
* [[Caroverine]] | * [[Caroverine]] | ||
| + | * [[Conantokin]] | ||
* [[D-α-Aminoadipate|<small>D</small>-αAA]] | * [[D-α-Aminoadipate|<small>D</small>-αAA]] | ||
* [[Dexanabinol]] | * [[Dexanabinol]] | ||
| Line 338: | Line 346: | ||
* [[MDL-27266]] | * [[MDL-27266]] | ||
* [[Metaphit]]<!--Irreversible--> | * [[Metaphit]]<!--Irreversible--> | ||
| + | * [[Minocycline]] | ||
| + | * [[2-Methyl-6-(phenylethynyl)pyridine|MPEP]] | ||
* [[Niflumic acid]] | * [[Niflumic acid]] | ||
* [[Pentamidine]] | * [[Pentamidine]] | ||
| Line 345: | Line 355: | ||
* [[Transcrocetin]] ([[saffron]]) | * [[Transcrocetin]] ([[saffron]]) | ||
| − | + | * '''Unsorted:''' ''Allosteric modulators:'' [[AGN-241751]] | |
| + | |below = | ||
| + | * '''''See also:''' [[Template:Receptor modulators|Receptor/signaling modulators]]'' | ||
| + | * ''[[Template:Metabotropic glutamate receptor modulators|Metabotropic glutamate receptor modulators]]'' | ||
| + | * ''[[Template:Glutamate metabolism and transport modulators|Glutamate metabolism/transport modulators]]'' | ||
}} | }} | ||
<noinclude> | <noinclude> | ||
| − | {{ | + | {{Collapsible option}} |
[[Category:Drug templates by receptor, channel, or pump]] | [[Category:Drug templates by receptor, channel, or pump]] | ||
</noinclude> | </noinclude> | ||
Latest revision as of 17:35, 1 August 2018
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Ionotropic glutamate receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Ionotropic glutamate receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Ionotropic glutamate receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.